Drugs that contain Enasidenib Mesylate

1. List of Idhifa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9512107 CELGENE CORP Therapeutically active compositions and their methods of use
Jan, 2033

(9 years from now)

US10093654 CELGENE CORP Therapeutically active compounds and their methods of use
Aug, 2034

(11 years from now)

US9738625 CELGENE CORP Therapeutically active compounds and their methods of use
Aug, 2034

(11 years from now)

US9732062 CELGENE CORP Therapeutically active compounds and their methods of use
Sep, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 CELGENE CORP Methods and compositions for cell-proliferation-related disorders
Jun, 2030

(7 years from now)

US10294215 CELGENE CORP Therapeutically active compounds and their methods of use
Jan, 2033

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 1, 2024
New Chemical Entity Exclusivity (NCE) Aug 1, 2022

NCE-1 date: August, 2021

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in